What is the appropriate dosing, contraindications, and monitoring for initiating trazodone in an adult patient with insomnia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trazodone Should NOT Be Used for Insomnia in Adults

The American Academy of Sleep Medicine explicitly recommends AGAINST using trazodone for the treatment of sleep onset or sleep maintenance insomnia in adults 1. This is a formal clinical practice guideline recommendation, despite trazodone being the second most commonly prescribed medication for insomnia in the United States 2, 3.

Why Trazodone Is Not Recommended

The guideline's negative recommendation is based on:

  • Insufficient efficacy evidence: Very limited data supporting trazodone's effectiveness for insomnia, with most studies being small, poorly designed, and conducted primarily in depressed populations rather than primary insomnia 2
  • Lack of objective sleep measures: Most available studies lack polysomnographic (objective) efficacy data 2
  • Significant adverse effects: High discontinuation rates due to sedation, dizziness, and psychomotor impairment—particularly concerning in elderly patients 2
  • Evidence of tolerance: Some data suggest tolerance develops with continued use 2

FDA-Approved Status and Off-Label Use

Trazodone is FDA-approved for major depressive disorder, NOT for insomnia 1. When used for insomnia, it represents off-label usage 1. The typical dose studied for insomnia was 50 mg 1, though real-world use ranges from 25-200 mg 4, 5.

If Trazodone Must Be Used: Dosing and Monitoring

Despite the guideline recommendation against its use, if clinical circumstances require trazodone:

Dosing

  • Starting dose: 25-50 mg at bedtime 6, 5
  • Therapeutic range for insomnia: 50-200 mg nightly (70% of patients respond in this range) 4
  • Antidepressant doses: 150-300 mg for full antidepressant effect 7, 5
  • Administration: Take shortly after a meal or light snack to optimize absorption 6
  • Titration: Increase gradually as needed, weighted toward bedtime dosing 7

Contraindications (from FDA labeling) 6

Absolute contraindications:

  • Concurrent MAOI use or within 14 days of discontinuing an MAOI
  • Initiation in patients being treated with linezolid or IV methylene blue

Relative contraindications/high-risk situations:

  • History of cardiac arrhythmias (trazodone prolongs QT interval) 6
  • Concurrent use with other QT-prolonging medications 6
  • Bipolar disorder (risk of manic activation) 6
  • History of priapism

Critical Monitoring Parameters

Cardiovascular monitoring:

  • Baseline ECG in patients with cardiac risk factors or on QT-prolonging drugs 6
  • Monitor for arrhythmias, particularly when combined with strong CYP3A4 inhibitors 6

Psychiatric monitoring:

  • Suicidality: Especially during initial treatment and dose changes 6
  • Mania/hypomania activation: Monitor for mood elevation, particularly in bipolar patients 6
  • Serotonin syndrome: When combined with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl, lithium) 6

Bleeding risk:

  • Increased risk when combined with antiplatelet agents (aspirin, NSAIDs) or anticoagulants (warfarin) 6
  • Monitor INR closely if on warfarin 6

Sexual function:

  • Priapism: Occurs in up to 12% of patients in some studies 4—far higher than previously recognized
  • Directly ask male patients about prolonged erections at each visit

Drug interactions requiring dose adjustment:

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): Use lower trazodone dose 6
  • Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May need higher trazodone dose 6
  • Digoxin/phenytoin: Monitor levels closely as trazodone increases their concentrations 6

Discontinuation:

  • Do NOT stop abruptly—taper gradually to avoid discontinuation syndrome 6

Common Pitfalls to Avoid

  1. Using trazodone as first-line for primary insomnia: Multiple FDA-approved alternatives exist with better evidence (zolpidem, eszopiclone, suvorexant, doxepin) 1

  2. Ignoring cardiac risk: Trazodone prolongs QT interval—avoid in patients with arrhythmias or on other QT-prolonging drugs 6

  3. Failing to ask about priapism: The 12% incidence in one study 4 is alarmingly high; this requires direct questioning

  4. Combining with multiple serotonergic agents: Risk of serotonin syndrome increases substantially 6

  5. Using in elderly without considering fall risk: Sedation and psychomotor impairment increase fall risk 2

  6. Assuming efficacy based on widespread use: Real-world data show 17.7% of insomnia patients are prescribed trazodone 3, but this reflects practice patterns, not evidence quality

Alternative Recommendations

For primary insomnia, the AASM guideline suggests (all WEAK recommendations):

  • Sleep onset insomnia: Zaleplon, zolpidem, triazolam, ramelteon 1
  • Sleep maintenance insomnia: Suvorexant, eszopiclone, zolpidem, doxepin 1
  • Both sleep onset and maintenance: Eszopiclone, zolpidem, temazepam 1

Trazodone may have a role in:

  • Depression with comorbid insomnia (its FDA-approved indication) 5, 8, 9
  • PTSD-related nightmares and insomnia 4
  • Patients who have failed or cannot tolerate FDA-approved hypnotics

The evidence quality for all insomnia medications is limited, but trazodone uniquely lacks sufficient data to support even a weak positive recommendation 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.